Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

17 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Electrocardiogram Abnormalities Form - GSK Milveterol COPD 100527

- 20/09/2021 - 1 Formulaire, 1 Groupe Item, 11 Eléments de données, 1 Langue
Groupe Item: Electrocardiogram Abnormalities
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Main CRF (Treatment Period 1, Day 1-2) - GSK Milveterol COPD 100527

- 20/09/2021 - 1 Formulaire, 16 Groupes Item, 123 Eléments de données, 1 Langue
Groupes Item: Investigational Product Day 1, Investigational Product Day 2, Hematology Day 1 Pre-Dose, Clinical chemistry Day 1 Pre-Dose, Urinalysis Day 1 Pre-Dose, Vital Signs Day 1, Vital Signs Day 2, 12-Lead Electrocardiogram Day 1, 12-Lead Electrocardiogram Day 2, FEV1 Day 1, Pharmacokinetic sampling Day 1, Potassium and Glucose Day 1, Pharmacokinetic Urine lnterval Collection Data Day 1, Hematology Day 1 Post-Dose, Clinical chemistry Day 1 Post-Dose, Urinalysis Day 1 Post-Dose
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Main CRF (Treatment Period 3, Day 1-2) - GSK Milveterol COPD 100527

- 20/09/2021 - 1 Formulaire, 16 Groupes Item, 123 Eléments de données, 1 Langue
Groupes Item: Investigational Product Day 1, Investigational Product Day 2, Hematology Day 1 Pre-Dose, Clinical chemistry Day 1 Pre-Dose, Urinalysis Day 1 Pre-Dose, Vital Signs Day 1, Vital Signs Day 2, 12-Lead Electrocardiogram Day 1, 12-Lead Electrocardiogram Day 2, FEV1 Day 1, Pharmacokinetic sampling Day 1, Potassium and Glucose Day 1, Pharmacokinetic Urine lnterval Collection Data Day 1, Hematology Day 1 Post-Dose, Clinical chemistry Day 1 Post-Dose, Urinalysis Day 1 Post-Dose
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Main CRF (Treatment Period 4, Day 1-2) - GSK Milveterol COPD 100527

- 20/09/2021 - 1 Formulaire, 16 Groupes Item, 123 Eléments de données, 1 Langue
Groupes Item: Investigational Product Day 1, Investigational Product Day 2, Hematology Day 1 Pre-Dose, Clinical chemistry Day 1 Pre-Dose, Urinalysis Day 1 Pre-Dose, Vital Signs Day 1, Vital Signs Day 2, 12-Lead Electrocardiogram Day 1, 12-Lead Electrocardiogram Day 2, FEV1 Day 1, Pharmacokinetic sampling Day 1, Potassium and Glucose Day 1, Pharmacokinetic Urine lnterval Collection Data Day 1, Hematology Day 1 Post-Dose, Clinical chemistry Day 1 Post-Dose, Urinalysis Day 1 Post-Dose
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Main CRF (Treatment Period 4, Day 7) - GSK Milveterol COPD 100527

- 20/09/2021 - 1 Formulaire, 13 Groupes Item, 100 Eléments de données, 1 Langue
Groupes Item: Hematology Day 7 Pre-Dose, Clinical chemistry Day 7 Pre-Dose, Urinalysis Day 7 Pre-Dose, Investigational Product Day 7, Vital Signs Day 7, 12-Lead Electrocardiogram Day 7, FEV1 Day 7, Pharmacokinetic sampling Day 7, Potassium and Glucose Day 7, Pharmacokinetic Urine lnterval Collection Data Day 7, Hematology Day 7 Post-Dose, Clinical chemistry Day 7 Post-Dose, Urinalysis Day 7 Post-Dose
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Main CRF (Treatment Period 3, Day 7) - GSK Milveterol COPD 100527

- 20/09/2021 - 1 Formulaire, 13 Groupes Item, 100 Eléments de données, 1 Langue
Groupes Item: Hematology Day 7 Pre-Dose, Clinical chemistry Day 7 Pre-Dose, Urinalysis Day 7 Pre-Dose, Investigational Product Day 7, Vital Signs Day 7, 12-Lead Electrocardiogram Day 7, FEV1 Day 7, Pharmacokinetic sampling Day 7, Potassium and Glucose Day 7, Pharmacokinetic Urine lnterval Collection Data Day 7, Hematology Day 7 Post-Dose, Clinical chemistry Day 7 Post-Dose, Urinalysis Day 7 Post-Dose
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Main CRF (Treatment Period 4, Day 3-6) - GSK Milveterol COPD 100527

- 20/09/2021 - 1 Formulaire, 6 Groupes Item, 46 Eléments de données, 1 Langue
Groupes Item: Vital Signs Day 3-6, 12-Lead Electrocardiogram Day 3-6, FEV1 Day 3-6, Pharmacokinetic sampling Day 5-6, Potassium Day 5-6, Investigational Product Day 3-6
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Main CRF (Treatment Period 3, Day 3-6) - GSK Milveterol COPD 100527

- 20/09/2021 - 1 Formulaire, 6 Groupes Item, 46 Eléments de données, 1 Langue
Groupes Item: Vital Signs Day 3-6, 12-Lead Electrocardiogram Day 3-6, FEV1 Day 3-6, Pharmacokinetic sampling Day 5-6, Potassium Day 5-6, Investigational Product Day 3-6
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Main CRF (Treatment Period 2, Day 7) - GSK Milveterol COPD 100527

- 20/09/2021 - 1 Formulaire, 13 Groupes Item, 100 Eléments de données, 1 Langue
Groupes Item: Hematology Day 7 Pre-Dose, Clinical chemistry Day 7 Pre-Dose, Urinalysis Day 7 Pre-Dose, Investigational Product Day 7, Vital Signs Day 7, 12-Lead Electrocardiogram Day 7, FEV1 Day 7, Pharmacokinetic sampling Day 7, Potassium and Glucose Day 7, Pharmacokinetic Urine lnterval Collection Data Day 7, Hematology Day 7 Post-Dose, Clinical chemistry Day 7 Post-Dose, Urinalysis Day 7 Post-Dose
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Main CRF (Treatment Period 1, Day 1-2) - GSK Milveterol COPD 100527

- 20/09/2021 - 1 Formulaire, 16 Groupes Item, 123 Eléments de données, 1 Langue
Groupes Item: Investigational Product Day 1, Investigational Product Day 2, Hematology Day 1 Pre-Dose, Clinical chemistry Day 1 Pre-Dose, Urinalysis Day 1 Pre-Dose, Vital Signs Day 1, Vital Signs Day 2, 12-Lead Electrocardiogram Day 1, 12-Lead Electrocardiogram Day 2, FEV1 Day 1, Pharmacokinetic sampling Day 1, Potassium and Glucose Day 1, Pharmacokinetic Urine lnterval Collection Data Day 1, Hematology Day 1 Post-Dose, Clinical chemistry Day 1 Post-Dose, Urinalysis Day 1 Post-Dose
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Main CRF (Treatment Period 1, Day 7) - GSK Milveterol COPD 100527

- 20/09/2021 - 1 Formulaire, 13 Groupes Item, 100 Eléments de données, 1 Langue
Groupes Item: Hematology Day 7 Pre-Dose, Clinical chemistry Day 7 Pre-Dose, Urinalysis Day 7 Pre-Dose, Investigational Product Day 7, Vital Signs Day 7, 12-Lead Electrocardiogram Day 7, FEV1 Day 7, Pharmacokinetic sampling Day 7, Potassium and Glucose Day 7, Pharmacokinetic Urine lnterval Collection Data Day 7, Hematology Day 7 Post-Dose, Clinical chemistry Day 7 Post-Dose, Urinalysis Day 7 Post-Dose
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Main CRF (Treatment Period 2, Day 1-2) - GSK Milveterol COPD 100527

- 20/09/2021 - 1 Formulaire, 16 Groupes Item, 123 Eléments de données, 1 Langue
Groupes Item: Investigational Product Day 1, Investigational Product Day 2, Hematology Day 1 Pre-Dose, Clinical chemistry Day 1 Pre-Dose, Urinalysis Day 1 Pre-Dose, Vital Signs Day 1, Vital Signs Day 2, 12-Lead Electrocardiogram Day 1, 12-Lead Electrocardiogram Day 2, FEV1 Day 1, Pharmacokinetic sampling Day 1, Potassium and Glucose Day 1, Pharmacokinetic Urine lnterval Collection Data Day 1, Hematology Day 1 Post-Dose, Clinical chemistry Day 1 Post-Dose, Urinalysis Day 1 Post-Dose
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial